November 24, 2016 - By Marguerite Chambers
In a note revealed on 24 November, Udg Healthcare Public Limited Company (LON:UDG) stock had its Add Rating reaffirmed by stock research analysts at numis. They currently have a GBX 730.00 target price on company. numis’s target would suggest a potential upside of 18.80% from the company’s previous stock close.
Out of 9 analysts covering UDG Healthcare PLC (LON:UDG), 8 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 89% are positive. GBX 750 is the highest target while GBX 5.15 is the lowest. The GBX 679.29 average target is 10.54% above today’s (GBX 614.5) stock price. UDG Healthcare PLC has been the topic of 42 analyst reports since July 31, 2015 according to StockzIntelligence Inc. Jefferies maintained the stock with “Buy” rating in Friday, September 30 report. The rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, November 24. As per Friday, January 29, the company rating was maintained by Davy Research. Jefferies maintained the stock with “Buy” rating in Tuesday, February 2 report. On Monday, July 25 the stock rating was maintained by Berenberg with “Buy”. The rating was maintained by Davy Research with “Outperform” on Thursday, August 4. The rating was maintained by Numis Securities on Wednesday, September 28 with “Add”. The firm has “Buy” rating given on Friday, June 3 by Berenberg. The company was upgraded on Tuesday, September 22 by N+1 Singer. The stock of Udg Healthcare PLC (LON:UDG) earned “Buy” rating by Berenberg on Friday, October 7.
The stock decreased 6.68% or GBX 44 on November 24, hitting GBX 614.5. About 1.61M shares traded hands or 213.11% up from the average. Udg Healthcare PLC (LON:UDG) has risen 9.66% since April 26, 2016 and is uptrending. It has outperformed by 4.25% the S&P500.
UDG Healthcare plc, formerly United Drug plc, is a healthcare services well-known provider in the Republic of Ireland, the United Kingdom, North America and Continental Europe. The company has a market cap of 1.50 billion GBP. The Firm operates in three divisions. It has a 33.02 P/E ratio. The Ashfield Commercial & Medical Services segment is engaged in the provision of sales, marketing and healthcare communications services to pharmaceutical companies, and it also provides sales teams, healthcare communications, telesales, nurse educators, medical information, pharmacovigilance, regulatory and event management services to over 300 healthcare companies in approximately 20 countries.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.